JP2017502686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502686A5 JP2017502686A5 JP2016553231A JP2016553231A JP2017502686A5 JP 2017502686 A5 JP2017502686 A5 JP 2017502686A5 JP 2016553231 A JP2016553231 A JP 2016553231A JP 2016553231 A JP2016553231 A JP 2016553231A JP 2017502686 A5 JP2017502686 A5 JP 2017502686A5
- Authority
- JP
- Japan
- Prior art keywords
- genbank accession
- accession number
- gene expression
- value
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900553P | 2013-11-06 | 2013-11-06 | |
| US61/900,553 | 2013-11-06 | ||
| PCT/US2014/064161 WO2015069790A1 (en) | 2013-11-06 | 2014-11-05 | Method for subtyping lymphoma types by means expression profiling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020018323A Division JP7016129B2 (ja) | 2013-11-06 | 2020-02-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502686A JP2017502686A (ja) | 2017-01-26 |
| JP2017502686A5 true JP2017502686A5 (https=) | 2017-12-14 |
| JP6657105B2 JP6657105B2 (ja) | 2020-03-04 |
Family
ID=51987470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553231A Active JP6657105B2 (ja) | 2013-11-06 | 2014-11-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
| JP2020018323A Active JP7016129B2 (ja) | 2013-11-06 | 2020-02-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020018323A Active JP7016129B2 (ja) | 2013-11-06 | 2020-02-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10607717B2 (https=) |
| EP (2) | EP3594359B1 (https=) |
| JP (2) | JP6657105B2 (https=) |
| KR (1) | KR102357699B1 (https=) |
| CN (1) | CN106232831B (https=) |
| AU (1) | AU2014346788B8 (https=) |
| CA (1) | CA2929826C (https=) |
| ES (2) | ES2738289T3 (https=) |
| WO (1) | WO2015069790A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| US20240430385A1 (en) * | 2015-04-16 | 2024-12-26 | Offender Smartphone Monitoring, LLC | Monitoring process |
| WO2016168667A1 (en) * | 2015-04-16 | 2016-10-20 | Offender Smartphone Monitoring, LLC | Monitoring process |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| CN108368554B (zh) * | 2015-09-29 | 2022-09-09 | Htg分子诊断有限公司 | 弥漫性大b细胞淋巴瘤(dlbcl)亚型分型的方法 |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| JP7075896B2 (ja) * | 2016-04-20 | 2022-05-26 | アメリカ合衆国 | マントル細胞リンパ腫の評価及びそれに関連する方法 |
| US9963748B2 (en) | 2016-05-13 | 2018-05-08 | Roche Molecular Systems, Inc. | Methods and compositions for classifying DLBCL |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| US11696250B2 (en) * | 2016-11-09 | 2023-07-04 | Intel Corporation | UE and devices for detach handling |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| EP3638814B8 (en) | 2017-06-14 | 2023-06-21 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Method for determining lymphoma type |
| ES2933256T3 (es) * | 2017-08-08 | 2023-02-03 | Hoffmann La Roche | Tratamiento con obinutuzumab de un subgrupo de pacientes con LDLBG |
| JP7517983B2 (ja) * | 2017-11-20 | 2024-07-17 | ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク | 非常に低レベルのｃｄ１９を発現する骨髄腫細胞を除去するｃｄ１９ｃａｒｔ細胞 |
| CN110945130B (zh) | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CA3083968C (en) | 2017-12-01 | 2024-04-23 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
| WO2019105437A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105435A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| EP3732185B1 (en) | 2017-12-29 | 2025-02-26 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| WO2020028563A1 (en) * | 2018-08-01 | 2020-02-06 | Genentech, Inc. | Prediction and characterization of dlbcl cell of origin subtypes |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| EP3862024A4 (en) | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020079591A1 (en) * | 2018-10-15 | 2020-04-23 | Provincial Health Services Authority | Gene expression profiles for b-cell lymphoma and uses thereof |
| MX2021005646A (es) * | 2018-11-14 | 2021-08-11 | Beyondspring Pharmaceuticals Inc | Métodos de tratamiento de cáncer con agentes de unión a tubulina. |
| US12496347B2 (en) | 2018-12-28 | 2025-12-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| AU2020245086B2 (en) * | 2019-03-28 | 2026-01-08 | Centre Henri Becquerel | Classification of B-Cell non-Hodgkin Lymphomas |
| CN111850114A (zh) * | 2019-04-25 | 2020-10-30 | 上海交通大学医学院附属瑞金医院 | 一组用于评估弥漫大b细胞淋巴瘤分子分型的基因群，其试剂盒及分析方法 |
| WO2020233651A1 (zh) * | 2019-05-22 | 2020-11-26 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610268B2 (ja) | 2019-05-22 | 2025-01-08 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| WO2020233680A1 (zh) | 2019-05-22 | 2020-11-26 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| AU2020280438B2 (en) | 2019-05-22 | 2025-03-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| EP3978609A4 (en) | 2019-05-24 | 2024-02-07 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| EP4682889A3 (en) * | 2019-07-22 | 2026-04-15 | F. Hoffmann-La Roche AG | Systems and methods for cell of origin determination from variant calling data |
| MX2022001812A (es) | 2019-08-12 | 2022-03-11 | Regeneron Pharma | Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos. |
| CN111621565B (zh) * | 2020-05-07 | 2023-12-15 | 杭州可帮基因科技有限公司 | 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置 |
| CN111785370B (zh) * | 2020-07-01 | 2024-05-17 | 医渡云（北京）技术有限公司 | 病历数据处理方法及装置、计算机存储介质、电子设备 |
| CN115955962B (zh) * | 2020-07-08 | 2024-07-12 | 代顿治疗股份公司 | 用于治疗淋巴肿瘤的沙铂 |
| JP2023536900A (ja) * | 2020-08-05 | 2023-08-30 | ティアークリアー コープ． | 眼科用製剤からの防腐剤除去のためのシステムおよび方法 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN113186289B (zh) * | 2021-05-12 | 2023-02-24 | 清华大学深圳国际研究生院 | lncRNA在肾癌尿液筛查和肾癌治疗中的应用 |
| CN119842823A (zh) * | 2024-12-25 | 2025-04-18 | 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） | SLC35E2B在Hacat细胞模型构建中的应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5252743A (en) | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
| DE69132905T2 (de) | 1990-12-06 | 2002-08-01 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Detektion von Nukleinsäuresequenzen |
| JP2001524926A (ja) | 1991-09-18 | 2001-12-04 | アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ | オリゴマーの雑多ライブラリーの集合体を合成する方法 |
| US5550215A (en) | 1991-11-22 | 1996-08-27 | Holmes; Christopher P. | Polymer reversal on solid surfaces |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| DE69233501T2 (de) | 1991-11-22 | 2006-02-23 | Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara | Kombinatorische Strategien für die Polymersynthese |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| US5491074A (en) | 1993-04-01 | 1996-02-13 | Affymax Technologies Nv | Association peptides |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US6090555A (en) | 1997-12-11 | 2000-07-18 | Affymetrix, Inc. | Scanned image alignment systems and methods |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| WO1995030774A1 (en) | 1994-05-05 | 1995-11-16 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US5599695A (en) | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
| US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
| WO1997043611A1 (en) | 1996-05-16 | 1997-11-20 | Affymetrix, Inc. | Systems and methods for detection of labeled materials |
| EP1027456B1 (en) | 1997-10-31 | 2005-03-16 | Affymetrix, Inc. (a Delaware Corporation) | Expression profiles in adult and fetal organs |
| US5936324A (en) | 1998-03-30 | 1999-08-10 | Genetic Microsystems Inc. | Moving magnet scanner |
| US6020198A (en) | 1998-09-25 | 2000-02-01 | Isis Pharmaceuticals Inc. | Antisense modulation of RIP-1 expression |
| US7105293B2 (en) | 2000-09-19 | 2006-09-12 | Whitehead Institute For Biomedical Research | Genetic markers for tumors |
| US20030194701A1 (en) | 2000-11-20 | 2003-10-16 | Golub Todd R. | Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| US7622260B2 (en) | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
| CN1273465C (zh) | 2001-09-21 | 2006-09-06 | 保宁制药株式会社 | 嘧啶酮化合物及其药学上可接受的盐的制备方法 |
| US7371736B2 (en) | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
| ES2542328T3 (es) | 2002-12-06 | 2015-08-04 | Millennium Pharmaceuticals, Inc. | Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma |
| NZ585188A (en) | 2003-08-15 | 2011-09-30 | Novartis Ag | 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| US20110152115A1 (en) | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| US8131475B2 (en) * | 2003-09-03 | 2012-03-06 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| EP2157524A3 (en) | 2003-09-03 | 2010-12-08 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| ATE514434T1 (de) | 2004-02-25 | 2011-07-15 | Dana Farber Cancer Inst Inc | Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum |
| EP1805197A1 (en) | 2004-09-27 | 2007-07-11 | Med Biogene Inc | Hematological cancer profiling system |
| US8349555B2 (en) | 2005-03-16 | 2013-01-08 | Gennadi V. Glinsky | Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures |
| MX2010005080A (es) * | 2007-11-07 | 2010-07-28 | Genentech Inc | Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40. |
| EP2245199B1 (en) * | 2008-02-01 | 2013-11-13 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
| US20110195064A1 (en) | 2008-06-06 | 2011-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Survival predictor for diffuse large b cell lymphoma |
| BR112012001077A2 (pt) | 2009-07-16 | 2020-08-11 | The General Hospital Corporation | extração de ácido nucleico, métodos para avaliar a qualidade de uma extração de ácido nucleico e de uma amostra biológica, para ober ácido nucleico a partir de uma amostra biológica, para analisar rna de microvesículas e para diagnosticar e monitorar um indivíduo, e, kit |
| ES2352777B1 (es) | 2009-07-31 | 2012-01-23 | Hospital Clinic De Barcelona | Metodo y kit para el pronostico del linfoma de celulas del manto |
| WO2011060272A2 (en) * | 2009-11-13 | 2011-05-19 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
| WO2011097476A1 (en) * | 2010-02-04 | 2011-08-11 | Indiana University Research And Technology Corporation | 4-protein biomarker panel for the diagnosis of lymphoma from biospecimen |
| EP2569335B1 (en) * | 2010-05-14 | 2018-08-22 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
| CN107898791A (zh) * | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
| US20120258878A1 (en) | 2010-08-04 | 2012-10-11 | Med Biogene Inc. | Prognostic gene signatures for non-small cell lung cancer |
| CA2834535A1 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| CA2858383A1 (en) | 2011-12-09 | 2013-06-13 | British Columbia Cancer Agency Branch | Predicting prognosis in classic hodgkin lymphoma |
| JP2015509489A (ja) | 2012-02-10 | 2015-03-30 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | がんの処置のためのグリシン開裂系の阻害 |
| US9803245B2 (en) | 2012-03-14 | 2017-10-31 | University Health Network | Signature for predicting clinical outcome in human HER2+ breast cancer |
| WO2013188600A1 (en) | 2012-06-12 | 2013-12-19 | Washington University | Copy number aberration driven endocrine response gene signature |
| WO2014197936A1 (en) | 2013-06-14 | 2014-12-18 | The State Of Queensland Acting Through Its Department Of Health | Biomarkers and use thereof in identification of b-cell lymphoproliferative disorders |
| IL278381B2 (en) | 2013-12-06 | 2024-08-01 | Celgene Corp | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
-
2014
- 2014-11-05 US US15/035,101 patent/US10607717B2/en active Active
- 2014-11-05 EP EP19170689.4A patent/EP3594359B1/en active Active
- 2014-11-05 JP JP2016553231A patent/JP6657105B2/ja active Active
- 2014-11-05 KR KR1020167014876A patent/KR102357699B1/ko active Active
- 2014-11-05 ES ES14803288T patent/ES2738289T3/es active Active
- 2014-11-05 ES ES19170689T patent/ES2923942T3/es active Active
- 2014-11-05 EP EP14803288.1A patent/EP3066215B1/en active Active
- 2014-11-05 CA CA2929826A patent/CA2929826C/en active Active
- 2014-11-05 AU AU2014346788A patent/AU2014346788B8/en active Active
- 2014-11-05 CN CN201480072382.7A patent/CN106232831B/zh active Active
- 2014-11-05 WO PCT/US2014/064161 patent/WO2015069790A1/en not_active Ceased
-
2020
- 2020-01-17 US US16/746,347 patent/US11574704B2/en active Active
- 2020-02-05 JP JP2020018323A patent/JP7016129B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502686A5 (https=) | ||
| Park et al. | Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin | |
| Eleveld et al. | RAS–MAPK pathway-driven tumor progression is associated with loss of CIC and other genomic aberrations in neuroblastoma | |
| Kowalski et al. | Genetic variants of CDH23 associated with noise-induced hearing loss | |
| Jinesh et al. | Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers | |
| Buccitelli et al. | Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation | |
| Vos et al. | Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma | |
| Zhou et al. | Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma | |
| US9670549B2 (en) | Gene expression signatures of neoplasm responsiveness to therapy | |
| Song et al. | Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients | |
| Kotsifaki et al. | Unveiling the immune microenvironment’s role in breast cancer: a glimpse into promising frontiers | |
| Dumeaux et al. | Peripheral blood cells inform on the presence of breast cancer: A population‐based case–control study | |
| JP2016515390A5 (https=) | ||
| Costa et al. | Extranodal NK-/T-cell lymphoma, nasal type: what advances have been made in the last decade? | |
| Douglas et al. | Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer | |
| Lynnhtun et al. | Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis | |
| JP2018518980A5 (https=) | ||
| Bemanian et al. | Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer | |
| Belenki et al. | Senescence-associated lineage-aberrant plasticity evokes T-cell-mediated tumor control | |
| Gupta et al. | Bridging the gap: cost-effective strategies for detecting Ph-like B-lineage ALL in resource-limited settings | |
| Miliotis et al. | Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci | |
| Kozakiewicz et al. | Spatial variation in gene expression of Tasmanian devil facial tumors despite minimal host transcriptomic response to infection | |
| Kim et al. | Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy | |
| TW201926094A (zh) | 三陰性乳癌的次分類及方法 | |
| Zhang et al. | Whole genome expression profiling shows that BRG1 transcriptionally regulates UV inducible genes and other novel targets in human cells |